Skip to main content

Advertisement

Table 3 Subgroup analysis of survival between two groups of BTC patients undergoing R0 resection

From: The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection

Variable 5-year OS rate (%) P value 3-year RFS rate (%) P value
Adjuvant chemotherapy Observation Adjuvant chemotherapy Observation
Tumor location
Gall bladder 62.5 52.3 0.057 69.7 58.1 0.148
Bile duct 35.2 26.9 0.577 30.8 12.5 0.720
Intrahepatic bile duct 27.5 0 0.265 22.8 32.5 0.549
Distal bile duct 72.9 50.0 0.014 70.0 25.0 0.016
Perihilar bile duct 0 66.7 0.139 0 33.3 0.066
Age (years)
<65 50.3 62.1 0.723 49.4 25.3 0.479
≥65 45.8 25.2 0.570 48.6 41.2 0.508
Lymph node involvement
Yes 23.0 23.8 0.121 21.7 15.6 0.222
No 57.9 39.6 0.587 59.3 44.2 0.336
CA 19-9 level (U/mL) a
<37 58.7 75.6 0.195 62.1 76.7 0.430
≥37 34.8 27.9 0.196 32.3 0 0.158
Histologic differentiation b
W/D 71.3 73.5 0.741 68.9 60.3 0.519
M/D or P/D 36.6 29.0 0.476 39.7 24.9 0.325
  1. OS overall survival, RFS recurrence-free survival, CA 19-9 carbohydrate antigen 19-9, W/D well-differentiated, M/D moderately differentiated, P/D poorly differentiated
  2. aBaseline CA 19-9 levels were unavailable for 12 patients in the adjuvant chemotherapy group and 15 patients in the observation group
  3. bSeven patients in the adjuvant chemotherapy group and 2 patients in the observation group had unspecified carcinoma